Savior Lifetec

Savior Lifetec Current Liabilities

The Current Liabilities of Savior Lifetec (4167.TWO) as of Oct 25, 2026 is 55.52 M TWD. In the previous year, Current Liabilities was 627.71 M TWD — a change of -91.16% (lower).

Current Liabilities

55.52 MTWD

YoY

-91.16%

Last updated:

Current Liabilities of Savior Lifetec is 2025 55.52 M TWD. Current Liabilities of Savior Lifetec was 2024 627.71 M TWD. It decreases by -91.16% lower compared to the previous year.

The Savior Lifetec Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2018
690.85 M TWD
Jan 1, 2019
1.78 B TWD
Jan 1, 2020
278.57 M TWD
Jan 1, 2021
145.07 M TWD
Jan 1, 2022
1.31 B TWD
Jan 1, 2023
141.58 M TWD
Jan 1, 2024
627.71 M TWD
Jan 1, 2025
55.52 M TWD
The Savior Lifetec Current Liabilities history
YEARCurrent LiabilitiesYoY
55.52 MTWD-91.16%
627.71 MTWD+343.36%
141.58 MTWD-89.23%
1.31 BTWD+805.94%
145.07 MTWD-47.92%
278.57 MTWD-84.32%
1.78 BTWD+157.18%
690.85 MTWD-37.39%
1.10 BTWD+10.82%
995.64 MTWD+7.30%
927.91 MTWD+12.82%
822.47 MTWD-11.50%
929.31 MTWD+163.47%
352.72 MTWD-26.05%
476.97 MTWD-28.79%
669.83 MTWD+45.01%
461.93 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Savior Lifetec Stock analysis

What does Savior Lifetec do? Savior Lifetec Corp develops, produces, and sells active pharmaceutical ingredients and finished dosage formulations, including Meropenem, Imipenem/Cilastatin, and Ertapenem, which are used as broad-spectrum antibiotics. The company provides APIs intermediates and bio-pharmaceutical technology services, distributing its products to Europe, the Americas, Asia, and other global markets. Its primary revenue streams come from the sale of pharmaceutical products and technology services to international markets. The company's product portfolio focuses on antibiotics such as Meropenem and Ertapenem, which are sold as finished dosage formulations. APIs intermediates are supplied to clients in the pharmaceutical industry, while bio-pharmaceutical technology services support clients in drug development and manufacturing. These offerings target global pharmaceutical companies seeking reliable supply chains and technical expertise. Savior Lifetec Corp's customers include pharmaceutical firms in Europe, the Americas, Asia, and other regions that require active pharmaceutical ingredients and specialized technology services. The company generates revenue through direct sales of its antibiotic formulations and API intermediates, as well as through contractual agreements for bio-pharmaceutical technology services. Savior Lifetec is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Savior Lifetec stock

Current Liabilities of Savior Lifetec is 55.52 M TWD in 2025.

Current Liabilities of Savior Lifetec changed from 627.71 M TWD to 55.52 M TWD, representing a -91.16% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Savior Lifetec since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Savior Lifetec historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Savior Lifetec

All Key Metrics — Savior Lifetec